Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients

Seoul National University

Status: Completed

Conditions: Covid19; Cancer

Treatments: Drug: COVID-19 vaccine

Study type: Observational

Funder types: Other

Identifiers

NCT04910295

H-2013-121-1206

Details and patient eligibility

About

Serum antibody titre against COVID-19 spike protein will be measured before, after the first dose, and after the second dose (when applicable) in cancer patients who are receiving or received anti-cancer drugs. Side effects of vaccination and actual incidence of COVID-19 will be monitored.

Enrollment: 112 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 20 years of age or older
• Patients who are receiving or received anti-cancer drugs
• Those who are not vaccinated against COVID-19 at the time of enrollment
• Written informed consent

Exclusion criteria

• Any contraindications to COVID-19 vaccines
• Those who were already vaccinated
• Those who are on immunosuppressants or infected with HIV
• Those who underwent organ transplantation
• Active infections (for example, pneumonia)